-"Xinshengyuan" is currently operating dozens of biomedical projects, breaking through the convention of "grinding one medicine every ten years"
Independent innovation benefits the people.
Zhangjiang Biomedical Valley will be ten years old this year, and hundreds of biomedical enterprises and research units are pregnant with more than one miracle. Shanghai Xinshengyuan Pharmaceutical Research Co., Ltd., which just moved into the "Medicine Valley" last year, is one of them.
The registered capital of 300,000 yuan has created a miracle in the field of biomedicine, which is famous for its large investment, long time-consuming and high risk-it was born less than five years ago as a pastime. More than 60 China and international invention patents, 5 clinical approvals, 12 new drug declarations, a multi-link general platform for new drug research and development, and technology transfer centers all over Asia have made international capital have to look at each other with new eyes.
The achievement of new drugs is "come quickly, go far"
The story of "grinding a medicine for ten years" is almost commonplace for biomedical research and development. However, on the technical service platform of Zhangjiang "Xinshengyuan", there are nearly 60 research projects in operation at present, and more than one new drug has entered the final "sprint" stage of research. "Recombinant human keratinocyte growth factor -2" is expected to obtain drug evidence within this year, which can promote wound healing and treat refractory ulcers such as diabetic ulcer and inflammatory bowel disease. The 80-acre factory building on Chongming Island is waiting for this vacancy. It is estimated that the cumulative sales revenue will reach 300 million yuan by 2008 after production. "Recombinant human proinsulin C peptide" and "recombinant ovarian cancer with idiotypic microantibodies" are not far from success, and the long-term complications of diabetes and ovary, mainly diabetic nephropathy, will encounter "nemesis".
At the beginning of this year, 17 biomedical achievements were "married" to Pakistan, and the contract amount created for Zhangjiang "New Student Source" exceeded100000 USD. Iran, Egypt, Saudi Arabia and India have also become the targets of technology transfer; At the same time, the core technologies of developed countries have gradually settled here. Among them, humanized antibody technology from France is mainly used to treat rejection after transplantation, and it is expected to apply for clinical trials this year; Anti-hepatitis B and AIDS drug technology from South Korea has entered the "screening" stage, and clinical practice is expected to begin at the end of this year and early next year. During the Eleventh Five-Year Plan period, the goal of "recreation" is to complete 60 clinical trial applications and new drug declarations.
Don't be a lonely "long distance runner"
Looking at Zhangjiang's list of "freshmen", there are only 100 full-time employees, but there are nearly 60 part-time scientific consultants. Zhang Yi, director and general manager, said frankly that this special staffing is the driving force for independent innovation of enterprises. Fifty or sixty scientific consultants, mostly scientists from universities, research institutes and hospitals. They came with inspiration and topics, looking for a series of answers before clinical, clinical and industrialization on the platform. In most R&D dramas, Zhang Jiang's "New Student Source" does not play the leading role, but plays almost all roles.
At that time, a team of 18 people started their business with first-class biotechnology drugs from three countries. The original intention of Zhangjiang as a "new student source" is to become a link between Industry-University-Research and promote the transformation of more high-tech achievements. Without funds, everyone survived for 9 months without salary; In the absence of experimental sites, they "guerrilla" in the laboratories of universities and research institutes; When we first received the service "order", everyone regarded it as a rare training. With the increase of training opportunities, Zhangjiang "freshmen" quickly became familiar with the whole process and details from basic research to industrialization, and also found their own independent innovation model; Instead of being a lonely long-distance runner, it is better to form a strong relay team-a series of new drug research and development platforms. At present, resources such as venues, equipment and consumables, which account for 70% to 80% of the cost of new drug research and development, can be enjoyed, and the direct investment before clinical practice has dropped to 2 million yuan.
The snowball of capital is getting bigger and bigger
If there are no accidents, Shanghai Xinshengyuan Biomedical Co., Ltd. will be listed on NASDAQ in the first half of this year, becoming "the first biomedical R&D share in China" with an estimated market value of 654.38 billion US dollars.
Such a high "return" actually stems from the first "personal bonus" for the transformation of high-tech achievements in Shencheng. Five years ago, Shanghai took the lead in promoting the "18 Articles" of science and technology (some provisions of Shanghai Municipality on promoting the transformation of high-tech achievements). Professor Song Houyan of Shanghai Medical University won the transfer income award of 3.04 million yuan for transferring the results of "recombinant streptokinase for injection" and became the "first person to allocate according to technical factors". Ren Jun, the founder and chairman of Zhangjiang New Sheng Yuan, was the third person to complete the project, and the registered capital of Zhangjiang New Sheng Yuan was 300,000 yuan. Over the years, Zhangjiang "Xinshengyuan" has successfully promoted seven high-tech achievements transformation projects with a contract value of 65.438+34 billion yuan-a wonderful "sequel" is being staged.
Xinmin Evening News